Skip to main content
. 2019 Aug 22;197(5):551–558. doi: 10.1007/s00408-019-00260-1

Fig. 1.

Fig. 1

Complaints among IPF patients using nintedanib, pirfenidone or neither (controls). *Value differs significantly from controls (p < 0.05). #Value differs significantly from other drug group (p < 0.05)